- Territory Manager - Brazil/South America
- Sales manager
- Head of Sales
- Medewerker Productmanagement
- Sales Manager - Germany
- Associate Director International Procurement: Produce - Berlin
- International Procurement Manager - Berlin
- Sales specialist Vertical Farming North America / Europe
- Key Account Manager | Fresh Produce | Hamburg
- International Business Developer Indoor Farming
Top 5 -yesterday
- AU: "I expect logistics to remain an issue for the coming 3 to 6 months"
- Whitefly prevention with liquid nutritional plant enhancer
- US: Uncertainty looms over possible flower shortages ahead of Valentine's Day
- Angel Fresh, a fresh-keeping product for fresh-cut flowers
- Modiform now sells only circular thermoformed pots
Top 5 -last week
Top 5 -last month
Rubik’s cube-like plant puzzle could lead to new pharmaceuticals
Several members and derivatives of a group of natural plant compounds called heteroyohimbines, are, or have potential to be, important in medicine. One called ajmalicine, for example, is used as a treatment for high blood pressure, and the oxidised alstonine shows promise as an anti-psychotic drug. Piecing together the puzzle of how these compounds are made in plants could have enormous potential for developing new and improved therapies.
But the heteroyohimbine puzzle is not a simple jigsaw in which the picture becomes clearer with each new piece discovered; it’s more like a Rubik’s cube. New research, published in Nature Communications by researchers working in Professor Sarah O’Connor’s laboratory at the John Innes Centre, reveals a crucial “twist” in the puzzle that could make the rest easier to solve.
Dr Evangelos Tatsis, a postdoctoral researcher at the John Innes Centre, and a first author of the work along with PhD student Anna Stavrinides, said: “The small group of heteroyohimbines are all stereoisomers of each other, that is, they all have the same molecular formula, but they differ in the way their atoms are arranged – just like a Rubik’s cube has the same number of coloured squares, but the way you twist the cube gives different patterns. Different stereoisomers have different biological activities, so we have been trying to understand how those different conformations arise, and why.”
In previous work the research team showed that an enzyme called THAS is involved in taking a precursor molecule called strictosidine aglycone (SA) and converting it into the heteroyohimbine molecule tetrahydroalstonine. However, it was not known how or why the different stereoisomers formed.
As a starting point, the group explored the transcriptome of the flowering plant Catharanthus roseus (Madagascar Periwinkle), a known source of tetrahydroalstonine, and found 14 candidate enzymes with very similar sequences to THAS. The scientists then expressed each of these enzymes in a different bacterial colony ‘fed’ with SA, and compared them to see which heteroyohimbines were produced.
Heteroyohimbine compounds were produced in four of the 14 experiments. In three of these, production of the heteryohimbines tetrahydroalstonine and mayumbine was very similar: a ratio of 85:15. The fourth enzyme, called HYS, gave a completely different production profile of ajmalicine, tetrahydroalstonine and mayumbine in a ratio of 55:27:15.
Dr Tatsis said: “Each of our four candidate enzymes had very similar structures, and each was given the same substrate to start with. But, one of them produced different heteroyohimbines in different amounts – why? By resolving the crystal structures of these four enzymes, we determined what was different about HYS, and found that a particular loop of amino acid sequence is important in producing these different stereoisomers.”
Conversion of SA into different heteroyohimbines seems to be a critical ‘branching point’ – after this, derivative ‘scaffolds’ can be further altered by other enzymes to produce a whole suite of alkaloid products with potentially useful and valuable properties.
The discovery of HYS, along with systems recently developed at the John Innes Centre to produce plant compounds in large quantities, means we might be able to not only solve this Rubik’s cube-like puzzle, but perhaps engineer improved or completely new compounds for use in medicine.
For more information:
Receive the daily newsletter in your email for free | Click here
Other news in this sector:
- 2022-01-19 Torenia Vertigo; starting 2022 with a win
- 2022-01-18 What's in a peony name: Sarah Bernhardt, Alexander Fleming and Shirley Temple
- 2022-01-17 Outdoor cyclamen bred for the hot and dry Mediterranean climates
- 2022-01-13 Australia: Iconic flower's genetic puzzle revealed
- 2022-01-13 Six new AAS national winners for 2022
- 2022-01-11 Three new videos present Lazzeri's poinsettia 2022 assortment
- 2022-01-10 Taiwan: New orchid variety bred for ease of cultivation
- 2022-01-10 Suñorita rose garners American Rose Society’s Award of Excellence
- 2022-01-07 Beekenkamp Plants introduces superstar 'Kayla Red' in new poinsettia catalogue
- 2022-01-07 Gene discovered crucial to making crop plants produce clonal seeds
- 2022-01-05 "Why are we breeding such ugly flowers?"
- 2021-12-24 Kenya: Roses and alstroemerias on display at open days United Selections
- 2021-12-23 Growth and physiological responses of seagrape seedlings to salt stress
- 2021-12-17 'A lovely, rare, and updated version of our popular Pulmonaria ‘Raspberry Splash’'
- 2021-12-17 Proven Winners Calycanthus earns Green Thumb Award
- 2021-12-16 “Danziger’s approach to innovation is in the breeding"
- 2021-12-14 “Relocating our breeding from the US to Ecuador has greatly benefited our customers”
- 2021-12-03 Texas hibiscus breeder honored
- 2021-11-26 Schreurs gerbera presents three new varieties in this video
- 2021-11-24 Chinese scientists breed edible lilies for red soil